Journal of Hepatology
Volume 47, Issue 4 , Pages 460-466 , October 2007

Neuroendocrine tumors metastatic to the liver: How to select patients for liver transplantation?

References 

  1. Solcia E, Capella C, Kloppel G, Heitz PU, Sobin LH, Rosai J. Endocrine tumours of the gastrointestinal tract. In:  Solcia E,  Kloppel G,  Sobin LH editor. Histologic typing of endocrine tumours. WHO international histological classification of tumours. Heidelberg-New York: Springer Verlag; 2000;p. 57–67
  2. Blonski WC, Reddy KR, Shaked A, Siegelman E, Metz DC. Liver transplantation for metastatic neuroendocrine: a case report and review of the literature. World J Gastroenter. 2005;7676–7683
  3. Sutcliffe R, Maguire D, Ramage J, Rela M, Heaton N. Management of neuroendocrine liver metastases. Am J Surg. 2004;187:39–46
  4. Que FG, Nagorney DM, Batts KP, Linz LJ, Kvols LK. Hepatic resection for metastatic neuroendocrine carcinomas. Am J Surg. 1995;10:36–43
  5. Martin JK, Moertel CG, Adson MA, Schutt AJ. Surgical treatment of functioning metastatic carcinoid tumors. Arch Surg. 1983;118:537–542
  6. Danforth DN, Gorden P, Brennan MF. Metastatic insulin-secreting carcinoma of the pancreas: clinical course and the role of surgery. Surgery. 1984;96:1027–1037
  7. Norton JA, Sugarbaker PH, Doppman JL, Welsey RA, Maton PN, Gardner JD, et al. Aggressive resection of metastatic disease in selected patients with malignant gastrinoma. Ann Surg. 1986;203:353–359
  8. Makridis C, Öberg K, Juhlin C, Rastad J, Johansson H, Lörelius LE, et al. Surgical treatment of mid-gut carcinoid tumors. World J Surg. 1990;14:377–386
  9. McEntee GP, Nagorney DM, Kvols LK, Moertel CG, Grant CS. Cytoreductive hepatic surgery for neuroendocrine tumors. Surgery. 1990;108:1091–1096
  10. Søreide O, Berstad T, Bakka A, Schrumpf E, Hanssen LE, Engh V, et al. Surgical treatment as a principle in patients with advanced abdominal carcinoid tumors. Surgery. 1992;111:48–54
  11. Carty SE, Jensen RT, Norton JA. Prospective study of aggressive resection of metastatic pancreatic endocrine tumors. Surgery. 1992;112:1024–1032
  12. Dousset B, Saint-Marc O, Pitre J, Soubrane O, Houssin D, Chapuis Y. Metastatic endocrine tumors: medical treatment, surgical resection, or liver transplantation. World J Surg. 1996;20:908–915
  13. Chen H, Hardacre JM, Uzar A, Cameron JL, Choti MA. Isolated liver metastases from neuroendocrine tumors: does resection prolong survival?. J Am Coll Surg. 1998;187:88–93
  14. Chamberlain RS, Canes D, Brown KT, Saltz L, Jarnagin W, Fong Y, et al. Hepatic neuroendocrine metastases: does intervention alter outcomes?. J Am Coll Surg. 2000;190:432–445
  15. Jaeck D, Oussoultzoglou E, Bachellier P, Lemarque P, Weber JC, Nakano H, et al. Hepatic metastases of gastropancreatic neuroendocrine tumors: safe hepatic surgery. World J Surg. 2001;25:689–692
  16. Sarmiento JM, Heywood G, Rubin J, Ilstrup DM, Nagorney DM, Que FG. Surgical treatment of neuroendocrine metatstases to the liver: a plea for resection to increase survival. J Am Coll Surg. 2003;197:29–37
  17. Yao KA, Talamonti MS, Nemcek A, Angelos P, Chrisman H, Skarda J, et al. Indications and results of liver resection and hepatic chemoembolization for metastatic gastrointestinal neuroendocrine tumors. Surgery. 2001;130:677–682
  18. Makowka L, Tzakis A, Mazzaferro V, Teperman L, Demetris AJ, Iwatsuki S, et al. Transplantation of the liver for metastatic endocrine tumors of the intestine and pancreas. Surg Gynecol Obstet. 1989;168:107–111
  19. Van Vilsteren FGI, Baskin-Bey ES, Nagorney DM, Sanderson SO, Kremers WK, Rosen CB, et al. Liver transplantation for gastropancreatic neuroendocrine cancers: defining selection criteria to improve survival. Liver Transpl. 2006;12:448–456
  20. Arnold R, Simon B, Wied M. Treatment of neuroendocrine GEP tumors with somatostatin analogues: a review. Digestion. 2000;62:84–91
  21. Öberg K. Neuroendocrine gastrointestinal tumors. A condense overview of diagnoses and treatment. Ann Oncol. 1999;10:S3–S8
  22. Lehnert T. Liver transplantation for metastatic neuroendocrine carcinoma: an analysis of 103 patients. Transplantation. 1998;27:1307–1312
  23. Le Treut Y, Delpero J, Dousset B, Cherqui D, Segol D, Mantiou G, et al. Results of liver transplantation in the treatment of metastatic neuroendocrine tumors. A 31-case French multicentric report. Ann Surg. 1997;4:355–364
  24. Olausson M, Friman S, Cahlin C, Nilsson O, Jansson S, Wangberg B, et al. Indications and results of liver transplantation in patients with neuroendocrine tumors. World J Surg. 2002;26:998–1004
  25. Fernandez JA, Robles R, Marin C, Hernandez Q, Sanchez Bueno F, Ramirez P, et al. Role of liver transplantation in the management of metastatic neuroendocrine tumors. Transplant Proc. 2003;35:1832–1833
  26. Rosenau J, Bahr MJ, von Wasielewski R, Mengel M, Schmidt HH, Nashan B, et al. Ki67, E-cadherin, and p53 as prognostic indicators of long-term outcome after liver transplantation for metastatic neuroendocrine tumors. Transplantation. 2002;15:386–394
  27. Cahlin C, Friman S, Ahlman H, Backman L, Mjornstedt L, Lindner P, et al. Liver transplantation for metastatic neuroendocrine tumor disease. Transplant Proc. 2003;35:809–810
  28. Florman S, Toure B, Kim L, Gondolesi G, Roayaie S, Krieger N, et al. Liver transplantation for neuroendocrine tumors. J Gastrointest Surg. 2004;8:208–212
  29. Arnold R, Trautmann ME, Creutzfeldt W, Benning R, Benning M, Neuhaus C, et al. Somatostatin analogue octreotide and inhibition of tumor growth in metastatic endocrine gastroenteropancreatic tumors. Gut. 1996;38:430–438
  30. Roskams T, van den Oord JJ, De Vos R, Desmet VJ. Neuroendocrine features of reactive bile ductules in cholestatic liver disease. Am J Pathol. 1990;137:1019–1025

☆ The authors declare that they do not have anything to disclose regarding conflict of interest with respect to this manuscript.

PII: S0168-8278(07)00399-6

doi: 10.1016/j.jhep.2007.07.004

Journal of Hepatology
Volume 47, Issue 4 , Pages 460-466 , October 2007

Article Tools

* Image Usage & Resolution